Hey Jane Real Customer Outcomes: An Independent Clinical Review

What Hey Jane Actually Offers and Who It Serves

Hey Jane positions itself as a reproductive and sexual health telehealth service designed around patient convenience, privacy, and access. It operates on a cash-pay model, meaning no insurance billing, which has real implications for cost and access depending on your income and state.

The service is primarily designed for women and people with uteruses in their reproductive years, though services like emergency contraception and STI treatment remain relevant through perimenopause. Clinicians on the platform prescribe via asynchronous intake (you fill out a form, a provider reviews and responds) or synchronous video visits depending on the service type.

What Hey Jane Prescribes

The core prescribing menu includes:

• Medication abortion (mifepristone plus misoprostol through 10 weeks gestational age)
• Emergency contraception (oral levonorgestrel or ulipristal acetate)
• Ongoing birth control (combined oral contraceptives, progestin-only pills, patch, ring)
• STI treatment (chlamydia, gonorrhea, BV, yeast infections in eligible patients)
• UTI treatment

This is a narrower formulary than full-service telehealth platforms like Wisp or Nurx, which also cover menopause hormone therapy, PCOS management, and thyroid care. If you are in perimenopause looking for estrogen therapy, Hey Jane is not the right service for you at this time.

Who Is Not a Good Fit

Hey Jane screens out patients with clinical contraindications. For medication abortion, those include confirmed ectopic pregnancy, IUD in place, certain bleeding disorders, and corticosteroid dependency. The platform relies on self-reported last menstrual period to estimate gestational age, which introduces a verification limitation that any patient with irregular cycles, including those with PCOS, should take seriously.

The Clinical Evidence Behind Hey Jane's Care Model

Reviewing Hey Jane's outcomes means reviewing the evidence base for the care model it uses, because Hey Jane does not publish independent peer-reviewed outcome data on its own patient population. This is a meaningful gap. What we can assess is how well the platform's protocols align with established clinical evidence for each service.

Medication Abortion by Telehealth: What the Data Show

The foundational question for Hey Jane's core service is whether telehealth-prescribed medication abortion is as safe and effective as in-clinic care. The answer, from multiple large trials, is yes, within appropriate gestational limits.

The TelAbortion Study, published in Obstetrics & Gynecology in 2021, followed 1,390 patients across multiple US states who received mifepristone plus misoprostol via mail after a telehealth visit. Complete abortion without surgical intervention occurred in 95% of participants, a rate consistent with in-clinic care. Serious adverse events occurred in fewer than 1% of patients.

A 2022 meta-analysis published in The Lancet covering over 22,000 telehealth medication abortion patients found completion rates between 95% and 98%, with no significant difference in serious adverse event rates compared to facility-based care.

ACOG Practice Bulletin 225 endorses medication abortion through 70 days (10 weeks) gestational age using the mifepristone 200 mg plus misoprostol 800 mcg buccal regimen. Hey Jane's protocol aligns with this guideline. The FDA's 2023 update to the mifepristone REMS removed the in-person dispensing requirement, explicitly permitting certified mail-order pharmacy dispensing, which is the pathway Hey Jane uses.

Emergency Contraception: Efficacy and the Weight Caveat

Hey Jane prescribes both levonorgestrel EC (Plan B and generics) and ulipristal acetate (ella). This matters for women in specific weight ranges. Published pharmacokinetic data show that levonorgestrel EC has reduced efficacy in people weighing over approximately 165-176 lbs (75-80 kg), with near-zero effectiveness documented above 176 lbs in some analyses.

Ulipristal acetate maintains better efficacy at higher body weights, though data above 195 lbs remain thin. A platform that does not proactively route higher-weight patients to ulipristal is missing a clinically meaningful step. Whether Hey Jane's intake form systematically captures this is not publicly documented.

Birth Control Prescribing

For combined hormonal contraceptives, standard telehealth safety screening applies. Hey Jane's intake forms should capture contraindications including personal or family history of VTE, migraine with aura, uncontrolled hypertension, and smoking status in women over 35.

Blood pressure is a particular concern. ACOG Committee Opinion 788 acknowledges that self-reported blood pressure carries limitations. Patients who have not had a recent blood pressure reading should measure it at a pharmacy kiosk before completing a combined hormonal contraceptive intake.

Pregnancy and Lactation Safety: What Every Patient Must Know

Mifepristone is the cornerstone of Hey Jane's most-used service. Its pregnancy and lactation profile requires clear explanation.

Mifepristone in Ongoing Pregnancy

Mifepristone (Mifeprex) is classified by the FDA as a drug used to end intrauterine pregnancy. It is not safe to continue a wanted pregnancy after mifepristone exposure. Animal studies and the limited human case data on inadvertent mifepristone exposure in ongoing pregnancies show risk of fetal limb defects, though absolute risk is not precisely quantified because the exposure scenario is rare.

Before accessing medication abortion through Hey Jane or any telehealth service, you must have a confirmed or reliably estimated intrauterine pregnancy at or under 70 days gestational age. Ectopic pregnancy must be excluded. If you have irregular cycles, PCOS, or are uncertain about your dates, an in-person ultrasound before proceeding is the safer choice.

Lactation Transfer

Mifepristone is excreted into breast milk at low levels. The manufacturer and most clinical sources recommend interrupting breastfeeding for 24-48 hours after mifepristone administration and discarding pumped milk during that window. Misoprostol is also detectable in breast milk but at low concentrations; infant exposure is considered clinically insignificant at the doses used for medication abortion, per the WHO Model List considerations for misoprostol use in reproductive health.

Contraception After Medication Abortion

Ovulation can return as early as 8 days after a medication abortion. ACOG Practice Bulletin 225 recommends initiating contraception immediately after medication abortion if ongoing pregnancy prevention is desired. Hey Jane should offer a contraception conversation or prescription at the same visit. If it does not prompt this, ask explicitly.

Sex-Specific Physiology: How Your Hormonal Status Affects These Services

PCOS and Gestational Age Estimation

Women with PCOS frequently have irregular menstrual cycles, making last-menstrual-period-based gestational age estimates unreliable. ASRM data show that anovulatory cycles are common in PCOS, meaning ovulation may have occurred far later than expected from LMP. Telehealth platforms that rely exclusively on LMP without offering or requiring ultrasound confirmation carry a real risk of underestimating gestational age in this population. Women with PCOS should flag this clearly during intake and strongly consider in-person ultrasound confirmation before medication abortion.

Perimenopause and EC Relevance

Perimenopause, typically the decade before the final menstrual period, involves irregular ovulation rather than absent ovulation. Women in their 40s who believe they are infertile due to cycle irregularity can and do become pregnant. Emergency contraception remains relevant and effective in perimenopausal women; there is no evidence that declining ovarian reserve reduces EC efficacy when ovulation does occur.

Combined Hormonal Contraceptives in Women Over 35

Women over 35 who smoke face a significantly elevated VTE and arterial thromboembolism risk with combined estrogen-containing contraceptives. The absolute contraindication threshold is smoking more than 15 cigarettes per day in women over 35, per WHO Medical Eligibility Criteria for Contraceptive Use (WHO MEC Category 4). Hey Jane's intake must capture this; if a provider does not ask about smoking and age together, that is a red flag.

Is Hey Jane Legit? Evaluating the Platform's Credibility

Legitimacy for a telehealth reproductive health service comes down to four factors: licensed clinicians, adherence to evidence-based protocols, REMS compliance for mifepristone, and transparent follow-up pathways.

Clinician Licensing

Hey Jane employs licensed clinicians including physicians and nurse practitioners who hold state licenses in the states they prescribe in. Asynchronous prescribing is legal in the states where Hey Jane operates. State-by-state regulatory environments for telehealth abortion remain in flux following the Dobbs decision; Hey Jane does not serve states with abortion bans.

REMS Compliance

Mifepristone is subject to the FDA's Risk Evaluation and Mitigation Strategy (REMS), which requires that prescribers be certified, pharmacies be certified, and patients sign a Patient Agreement Form. The current REMS, updated in 2023, permits mail dispensing through certified mail-order pharmacies. Hey Jane uses certified pharmacy partners, which means its dispensing model is legally compliant at the federal level as of early 2025.

Follow-Up Pathway

One area where Hey Jane has received criticism from reproductive health researchers is the adequacy of follow-up for incomplete abortions. The TelAbortion Study used serum hCG and patient-reported symptom assessment for follow-up. Published data from that study show that the safety profile was non-inferior to in-clinic care, but only when a structured follow-up pathway was in place. Patients using Hey Jane should clarify before starting: what happens if you have heavy bleeding, what the protocol is for suspected incomplete abortion, and whether the platform covers follow-up visits or connects you to local emergency resources.

Hey Jane vs. Alternatives: A Clinical Comparison by Service Type

Not every reproductive health telehealth platform covers the same ground. Here is how Hey Jane compares for the most clinically common needs:

| Service Need | Hey Jane | Nurx | Wisp | Plan C (resource only) | |---|---|---|---|---| | Medication abortion | Yes (select states) | Yes (select states) | No | Resource list only | | Birth control | Yes | Yes | Yes | No | | Emergency contraception | Yes | Yes | Yes | No | | Menopause HRT | No | No | Yes | No | | PCOS management | No | No | Limited | No | | STI treatment | Yes | Yes | Yes | No | | UTI treatment | Yes | Yes | Yes | No |

If you need menopause hormone therapy, PCOS evaluation, thyroid management, or bone health assessment, you need a different service. Hey Jane is not a comprehensive women's health platform. It is a focused reproductive and sexual health service, and that focus has both clinical advantages (depth of protocol expertise in its lane) and real gaps.

Cost Comparison

Hey Jane's medication abortion service costs approximately $350-$650 depending on state, gestational age, and follow-up services. Nurx and Aid Access offer lower price points in some cases, with Aid Access serving all states including those with restrictions via international prescriber models that carry their own legal complexity. For birth control, Hey Jane's pricing is competitive with Nurx and The Pill Club at the time of publication, but cash-pay means no insurance offset.

A 2023 CDC report on contraceptive access noted that cost remains the single most commonly cited barrier to consistent contraception use among women aged 18-44 in the US. Cash-pay models like Hey Jane's remove some barriers (no insurance authorization delays) while creating others (out-of-pocket cost).

What Real Outcomes Data Exist, and What Is Missing

Hey Jane does not publish a peer-reviewed outcomes report on its own patient population. This is not unusual for telehealth startups, but it is a transparency limitation. What clinical reviewers at WomanRx can assess is alignment with the published evidence base.

The strongest independent statement on telehealth medication abortion safety comes from a 2022 ACOG Clinical Practice Update, which concluded that "medication abortion provided via telehealth is as safe and effective as in-person medication abortion care when patients are appropriately screened and followed." The word "appropriately" carries weight here. The safety profile of the model depends entirely on the rigor of the intake screening and the robustness of the follow-up pathway. Neither can be fully evaluated by an external reviewer without access to Hey Jane's internal protocol documents.

Patient-reported satisfaction data pulled from independent review aggregators (not Hey Jane's own testimonials) consistently cite fast response times, discreet packaging, and clinical professionalism as positives. Complaints cluster around delayed shipping in states with pharmacy partner limitations and inadequate follow-up communication when complications arose. Neither category has been formally studied in peer-reviewed literature specific to Hey Jane.

Who This Service Is Right For, and Who Should Go Elsewhere

Based on the clinical evidence review above, Hey Jane is a reasonable option for women who:

• Live in a state where it operates and need medication abortion through 10 weeks with confirmed intrauterine pregnancy
• Need birth control or emergency contraception and have no complex contraindications
• Want a privacy-prioritizing, cash-pay model without an in-person visit
• Have regular cycles and reliable LMP-based gestational dating

You should seek in-person or broader telehealth care if you:

• Have PCOS with irregular cycles and need gestational age confirmation before medication abortion
• Are over 35 and need a full cardiovascular risk assessment before starting estrogen-containing contraception
• Are in perimenopause and need hormone therapy, bone health assessment, or PCOS management
• Have had a prior ectopic pregnancy or risk factors that require ultrasound exclusion of ectopic
• Are postpartum and breastfeeding and need nuanced lactation-safe contraception counseling
• Need HSDD, thyroid, or metabolic care

The strongest clinical case for Hey Jane is access. In states where reproductive healthcare is geographically or logistically inaccessible, a telehealth model with a 95-98% efficacy medication abortion protocol and REMS-compliant dispensing represents a genuine clinical benefit for appropriate candidates. Access is not a marketing claim. It is a measurable health outcome. A 2020 study in Contraception found that patients in rural areas faced median travel distances of 40 miles or more to the nearest abortion facility, with telehealth reducing that barrier to zero for eligible patients.

If you are in one of Hey Jane's service states and you are a clinical candidate for its services, confirm three things before proceeding: your gestational age is confirmed or confirmable, you have a clear emergency pathway if complications arise, and you receive a contraception discussion before or at the time of your medication abortion appointment.